Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

'Transformative' Dupilumab Set For Third Quarter Filing In Atopic Dermatitis

This article was originally published in Scrip

Executive Summary

Sanofi and Regeneron Pharmaceuticals Inc. are on schedule to file for approval of dupilumab for the treatment of atopic dermatitis in the third quarter of this year following positive data from two Phase III studies, SOLO 1 and SOLO 2.


Related Content

10 Approvals To Watch For In Early 2017
Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C
Maruho Broadens Derma Horizons Through Dual Licensing Deals
Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds
Galderma Steps Into Biologics With Chugai Eczema Antibody
Atopic Dermatitis: Ziarco Hopes Oral Therapy Will Trump Injectable Biologics
1Q Earnings Preview: What To Expect From US, EU Big Hitters